Details

Autor(en) / Beteiligte

• Arnaoutakis, Konstantinos
• Shaw, Alice T
• Solomon, Benjamin J

Titel

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

Ist Teil von

• The New England journal of medicine, 2015-02, Vol.372 (7), p.683-684

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• To the Editor: In the study reported by Shaw et al. (Nov. 20 issue), 1 crizotinib appears to be more potent against the gene encoding ROS1 proto-oncogene receptor tyrosine kinase ( ROS1 ) than against anaplastic lymphoma kinase (ALK) in non–small-cell lung cancers (NSCLCs), at least in vitro. The study also showed no apparent pharmacokinetic differences between patients with ALK rearrangements and those with ROS1 rearrangements. It would be interesting to know how many (if any) patients received a dose reduction of crizotinib, as well as the outcomes in these patients. I would like to know whether a lower dose of . . .